Immobilisation Technology for Next Generation Antibodies
Follow Us: fp-li fp-tw fp-rss
  • qm1w2 ADC Bio brings knowledge, experience and technical differentiation to the rapid growth ADC sector and is an ideal partner for basic research, development, scale-up and commercialisation challenges. qm2w2
  • qm1w2g Lock-Release features smaller production and containment footprints, minimized risk to high value drug components, lower costs and reduced environmental impact. qm2w2

ADC Biotechnology at-a-glance:

ADC Bio is developing new process technology to help drug developers meet conjugation process challenges in the testing and production of new antibody drug conjugate (ADC)-based anti cancer drugs. The technology signals faster, simpler and less costly development for an exciting new family of drugs.

With surging numbers of "second generation" drugs in development (currently around 200) tumour-selective ADCs are building a significant position in the oncology field – the fastest growing sector in healthcare.

For ADC developers, the key pre-clinical challenges for regulatory compliance with Chemistry Manufacturing Controls notably include unwanted aggregation, achieving the right Drug Antibody Ratio (DAR), a shortage of conjugation-qualified CMOs and removal of unbound drug from the product.

Reaching an optimal DAR and limiting aggregation to acceptable levels are closely linked, and ADC Bio's Lock-Release technology has proven to be a key product enabler in meeting this twin challenge. Lock Release facilitates maximum cell killing efficacy at higher DARs and at a quality - minimal aggregate and unbound drug - suitable for pivotal pre-clinical and clinical testing.

By effectively addressing these and other challenges, ADC Bio's technology aims to become a new paradigm in the way ADCs are developed and manufactured, increasing accessibility for patients by helping to contain ADC production complexity and cost.

ADC Bio's patented Lock - Release technology results in fast, simple and robust conjugation processes, with the potential to eliminate several process steps whilst enhancing product quality.

Following a successful proof-of-concept programme ADC Bio secured a £450,000 package of investment and grant funding in late 2011. A £600,000 second round investment and grant package was announced in January 2013.

Prototype Lock - Release platforms are currently under evaluation by key clients.

ADC Bio brings knowledge, experience and technical differentiation to the rapid growth ADC sector and is an ideal partner for basic research, development, scale-up and commercialisation challenges.



By 2015/16, the combined annual sales and production market for ADC drugs is projected to top US $8bn. ADC Bio's mission is to provide a superior conjugation technology platform that enables a new generation of anti-cancer therapeutics and diagnostics... offering rapid conjugation screening, efficient processing and improved development and production economics to drug innovators....


  Latest News

25 September 2017

ADC Bio to invest $11m on Bioconjugation facility

Customer demand for ‘Lock-Release’ aggregation control technology a key driver behind expansion into clinical & commercial drug manufacturing.

25 September, 2017, Wales: ADC Biotechnology (ADC Bio) – a specialist ADC contract services company with proprietary conjugation technology designed to overcome process and aggregation challenges during the development of new antibody drug conjugates (ADCs) – announces it has secured investment for the construction of an $11 million* bioconjugation facility at its new site in Deeside, North Wales, UK.

The 6,500m2 facility – scheduled to be operational by December 2018 – will support manufacturing in all clinical phases and small-scale commercial production of antibody drug conjugates. It will provide GMP production suites equipped with vessels of 10 up to a few hundred litres for batch sizes from 100 grams up to a kilo. The new integrated facility will enable ADC Bio to complement its long established technical services business that provides small scale R&D through to pre-clinical testing, with three on site laboratories and analytical testing capabilities.